Brief: AB Science Says New Independent Research Reveals Masitinib Has Direct Anti-Viral Activity Against SARS-CoV-2 Virus In Vitro
02/09/2020 19:32
Sept 2 (Reuters) - AB Science SA ABS.PA :
* AB SCIENCE: NEW INDEPENDENT RESEARCH REVEALS THAT
MASITINIB HAS
DIRECT ANTI-VIRAL ACTIVITY AGAINST SARS-COV-2 VIRUS IN VITRO AND
IS A PROMISING CANDIDATE FOR TREATING COVID-19
* AB SCIENCE SA - IN STUDY, MASITINIB SIGNIFICANTLY
INHIBITED
SARS-COV-2 REPLICATION IN HUMAN LUNG CELLS
* AB SCIENCE SA - IN STUDY, MASITINIB WAS ALSO EFFECTIVE IN
BLOCKING REPLICATION OF MULTIPLE PICORNAVIRUSES
Source text for Eikon: ID:nGNX7DcyMj
Further company coverage: ABS.PA
((reuters.briefs@thomsonreuters.com;))
Recent news on AB Science SA
See all newsBrief: AB Science Temporarily Halts Europe Clinical Trials Ahead Of Strategic Reorganization
Brief: AB Science Says FDA Granted Status Of Minor Use In Major Species For Masivet
Brief: AB Science Says Co Received Japanese Patent Protection To Use Masitinib In Progressive MS Until 2041
Brief: AB Science Phase 1 AML Study Of AB8939 Shows 100% Partial Response Rate
Brief: AB Science Receives Notice Of Allowance For European Patent Covering Masitinib Until 2040 In Treatment Of Sickle Cell Disease